Shield Therapeutics Banner Image

Shield Therapeutics

  • Ticker STX
    Exchange LSE More
  • Industry Drug Manufacturers - Other More
  • Sector Healthcare More
Shield Therapeutics Logo Image
  • 11-50 Employees
  • Based in Gateshead, England
Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of late-stage pharmaceuticals to treat unmet medical needs. The company's lead product is Ferric Maltol, marketed in the European Union as Feraccru, a non-salt based oral therapy for the treatment of iron deficiency with or without anaemia in adults. It also develops PT20, a novelMore therapy that has completed its Phase II pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease; PT30 to treat hypo-allergenic IV iron therapy; and PT40, the first generic version of iron sucrose. The company was founded in 2008 and is based in Gateshead, the United Kingdom.
4.8 / 5.0 (79)

Shield Therapeutics reports have an aggregate usefulness score of 4.8 based on 79 reviews.

Shield Therapeutics

Most Recent Annual Report

Shield Therapeutics
MOST RECENT 2023 Annual Report

Older/Archived Annual Reports

Shield Therapeutics Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!